Navigation Links
FDA Advisory Panel Recommends Approval of the SEDASYS(R) System
Date:5/28/2009

Panel Votes in Favor of Use by Physician/Nurse Teams to Deliver Minimal-to-Moderate Propofol Sedation

CINCINNATI, May 28 /PRNewswire/ -- Ethicon Endo-Surgery today announced that the Anesthesiology and Respiratory Therapy Devices Advisory Committee of the U.S. Food and Drug Administration (FDA) voted in favor of approval of the SEDASYS(R) System for use by physician/nurse teams to administer minimal-to-moderate propofol sedation during screening and diagnostic procedures for colorectal cancer (colonoscopy) and the upper gastrointestinal tract (EGD). The SEDASYS(R) System, the first computer-assisted personalized sedation (CAPS) system, integrates drug delivery and patient monitoring to enable propofol sedation personalized to each patient's needs.

The Anesthesiology and Respiratory Therapy Devices Advisory Committee voted 8 to 2 in favor of approval. Conditions of approval recommended by the Panel included that the SEDASYS(R) System only be used in adult patients age 70 and under, a comprehensive training program, definition of the sedation delivery team and a post-approval study. The final decision regarding approval of the device is made by the FDA.

"There is strong clinical support that the SEDASYS(R) System reduces the risk of over-sedation, which may help make sedation more predictable and reliable for physician/nurse teams," said Kenneth Sumner, Ph.D., Vice President, Clinical and Regulatory Affairs, Ethicon Endo-Surgery, Inc. "We look forward to continuing discussions with the FDA during the regulatory review process."

The Advisory Committee reviewed results from a recent pivotal trial, which were included in the company's Pre-Market Approval (PMA) application for the SEDASYS(R) System. In the study, patients who received sedation with the SEDASYS(R) System experienced fewer and less significant oxygen desaturation events, a clinical sign of over-sedation, than patients sedated with the current standard of care drugs -- benzodiazepines and opioids.

The SEDASYS(R) System automatically detects and responds to signs of over-sedation (oxygen desaturation and low respiratory rate/apnea), guided by continual monitoring and recording of critical patient vital signs, including oxygen saturation, respiratory rate, heart rate, blood pressure, end-tidal carbon dioxide and patient responsiveness.

Propofol (also known as DIPRIVAN(R)) is considered by physicians to be a preferred sedative due to its rapid onset and quick, clear-headed recovery, which enables patients to promptly return to normal activities following a colonoscopy or EGD procedure. Current propofol labeling states only persons trained in the administration of general anesthesia should administer the drug. In the majority of practice settings, gastroenterologists do not have broad access to anesthesiologists.

About the SEDASYS(R) System

The SEDASYS(R) System is the first computer-assisted personalized sedation (CAPS) system designed for physician/nurse teams to provide minimal-to-moderate sedation levels with propofol. By integrating drug delivery and patient monitoring, the SEDASYS(R) System enables physician/nurse teams to deliver personalized sedation. It automatically detects and responds to signs of over-sedation (oxygen desaturation and low respiratory rate/apnea) by stopping or reducing delivery of propofol, increasing oxygen delivery and automatically instructing patients to take a deep breath. The device is currently an investigational device limited by U.S. law to investigational use only.

About Ethicon Endo-Surgery

Ethicon Endo-Surgery, a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at www.ethiconendo.com.

(C)2009 Ethicon Endo-Surgery

SEDASYS(R) is a trademark of Ethicon Endo-Surgery.

DIPRIVAN(R) is a registered trademark of the AstraZeneca group of companies.

    CONTACTS:  Media:                  Investor Relations:
               Kelly Leadem            Stan Panasewicz
               Ethicon Endo-Surgery    Johnson & Johnson
               513-337-1006            732-524-2524
               973-713-6927

               Wendy Dougherty         Louise Mehrotra
               Ethicon Endo-Surgery    Johnson & Johnson
               513-337-8281            732-524-6491
               513- 293-0254


'/>"/>
SOURCE Ethicon Endo-Surgery
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
2. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
3. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
4. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
5. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
6. New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties
7. Arpida Comments on FDAs Anti-infective Drugs Advisory Committee Outcome
8. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
9. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
10. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
11. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 ... , la première endoprothèse à double ... à l,intervention portant sur les membres inférieurs ... OrbusNeich, entreprise mondiale spécialisée dans la ... la vie, a élargi son portefeuille pour ...
(Date:5/23/2016)... , May 23, 2016 ... "Patient Handling Equipment Market by Product (Wheelchair, Scooters, ... Care (Bariatric Care, Critical Care, Wound), Accessories (Lifting, ... Forecast to 2021", published by MarketsandMarkets, the patient ... 17.18 Billion by 2021 at a CAGR of ...
(Date:5/23/2016)... , May 23, 2016 ... Market Size, Share, Development, Growth and Demand Forecast ... Single and Other), by Application (Drug Discovery and ... End Users (Pharmaceuticals, Life Science and Biotechnology, Academic ... P&S Market Research, the global mass spectrometry ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... CloudLIMS, joins an elite number ... Sciences Tech Solution Providers list of 2016 by CIOReview. , In a deliberate session ... Sciences Tech Solution Providers 2016 has been concluded with. The positioning is based on ...
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular Imaging ... Molecular Imaging.” The focus of ADDMI-IG will be geared towards how using molecular ... issues. Through ADDMI-IG WMIS will provide a platform for productive discussions about the ...
(Date:5/25/2016)... ... 2016 , ... DKT International, one of the largest private ... to release their 2015 global impact data. In 2015, DKT served over 30 ... and 3.8 million unsafe abortions across 21 countries worldwide. , “We are ...
(Date:5/25/2016)... ... 2016 , ... Afrimesure specializes in providing clients with ideal ... and HVAC facilities. Their knowledgeable staff also takes care of the installation, IQ/OQ/PQ ... offers a variety of MadgeTech systems available for sterilization and temperature monitoring, including ...
(Date:5/25/2016)... ... May 25, 2016 , ... Casa Velas, an adults-only boutique hotel ... stones to complement its new wellness suites . The two 1,350 sq. ft. ... plethora of special services and insuite amenities, from a custom soap selection and in-suite ...
Breaking Medicine News(10 mins):